相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma
Chloe Steen et al.
CANCER CELL (2021)
The tumor microenvironment of lymphomas: Insights into the potential role and modes of actions of checkpoint inhibitors
Thomas Menter et al.
HEMATOLOGICAL ONCOLOGY (2021)
Evolving insights into the genomic complexity and immune landscape of diffuse large B-cell lymphoma: opportunities for novel biomarkers
Siba El Hussein et al.
MODERN PATHOLOGY (2020)
Role of the IL-2 inducible tyrosine kinase ITK and its inhibitors in disease pathogenesis
Kristina S. Lechner et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2020)
PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation
Matthew J. Frigault et al.
BLOOD ADVANCES (2020)
Role of Microenvironment in Non-Hodgkin Lymphoma Understanding the Composition and Biology
Arushi Khurana et al.
CANCER JOURNAL (2020)
Immune and Cell Therapy in Non-Hodgkin Lymphoma
Reid W. Merryman et al.
CANCER JOURNAL (2020)
T-cell inflamed tumor microenvironment predicts favorable prognosis in primary testicular lymphoma
Suvi-Katri Leivonen et al.
HAEMATOLOGICA (2019)
Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL
Ziju Y. Xu-Monette et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Pembrolizumab for the treatment of diffuse large B-cell lymphoma
Semira Sheikh et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2019)
Gene expression profiles analysis identifies a novel two-gene signature to predict overall survival in diffuse large B-cell lymphoma
Chengtao Sun et al.
BIOSCIENCE REPORTS (2019)
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial
Frederick L. Locke et al.
LANCET ONCOLOGY (2019)
PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program
Ling Li et al.
MODERN PATHOLOGY (2019)
The role of pembrolizumab in relapsed/refractory primary mediastinal large B-cell lymphoma
Sarah Tomassetti et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2019)
CAR T cell therapy for B-cell lymphomas
Julio C. Chavez et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2018)
Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue
S. Ciavarella et al.
ANNALS OF ONCOLOGY (2018)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Lenalidomide for the treatment of B-cell lymphoma
Sylvain Garciaz et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2016)
Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma
Tatyana Feldman et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Double hit lymphoma: the MD Anderson Cancer Center clinical experience
Yasuhiro Oki et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
pRRophetic: An R Package for Prediction of Clinical Chemotherapeutic Response from Tumor Gene Expression Levels
Paul Geeleher et al.
PLOS ONE (2014)
Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines
Paul Geeleher et al.
GENOME BIOLOGY (2014)
The tumour microenvironment in B cell lymphomas
David W. Scott et al.
NATURE REVIEWS CANCER (2014)
Higher Response to Lenalidomide in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Nongerminal Center B-Cell-Like Than in Germinal Center B-Cell-Like Phenotype
Francisco J. Hernandez-Ilizaliturri et al.
CANCER (2011)
CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group
Michael Pfreundschuh et al.
LANCET ONCOLOGY (2011)
Standard International Prognostic Index Remains a Valid Predictor of Outcome for Patients With Aggressive CD20+ B-Cell Lymphoma in the Rituximab Era
Marita Ziepert et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
AA Alizadeh et al.
NATURE (2000)
分享论文
